FAM3C‐YY1 axis is essential for TGFβ‐promoted proliferation and migration of human breast cancer MDA‐MB‐231 cells via the activation of HSF1

Weili Yang, Biaoqi Feng, Yuhong Meng, Junpei Wang, Bin Geng, Qinghua Cui, Hongquan Zhang, Jichun YangJournal of Cellular and Molecular Medicine 2019 · DOI

TL;DR

This study uncovers a novel signaling pathway involving FAM3C, YY1, and HSF1 that is crucial for the proliferation and migration of breast cancer cells, particularly when stimulated by TGF-β. The findings suggest that targeting this FAM3C-YY1-HSF1 axis could be a promising therapeutic strategy for breast cancer.

What Problem Does This Paper Address?

Breast cancer remains a significant global health challenge, and understanding the intricate molecular mechanisms driving its progression is vital for developing effective treatments. While individual factors like FAM3C, HSF1, and YY1 have been implicated in cancer, their coordinated roles and how they interact, especially in response to growth factors like TGF-β, were not well understood. This paper aims to elucidate the interplay between FAM3C, YY1, and HSF1 in promoting breast cancer cell proliferation and migration, and to define their role in TGF-β-driven tumorigenesis.

Methods

The researchers employed a multi-faceted approach using human breast cancer cell lines (MDA-MB-231 and BT-549) and human breast cancer tissues. Key techniques included:

  • Molecular Biology Techniques:
    • Overexpression and Silencing: Using adenoviral vectors (Ad-FAM3C) to overexpress FAM3C and small interfering RNA (siRNA) to silence FAM3C and YY1.
  • Western Blotting: To assess protein levels of FAM3C, YY1, HSF1, phosphorylated Akt (pAkt), Akt, and Cyclin D1.
  • Quantitative Real-Time PCR (qRT-PCR): To measure mRNA levels of FAM3C, YY1, HSF1, and Cyclin D1.
  • Luciferase Reporter Assay: To investigate the direct transcriptional regulation of HSF1 by YY1.
  • Cellular Assays:
    • Cell Counting and Viability Assays (MTT): To evaluate cell proliferation and survival.
  • Cell Cycle Analysis (Flow Cytometry): To determine the distribution of cells in different phases of the cell cycle.
  • Wound Healing Assay and Transwell Migration Assay: To assess cell migration capabilities.
  • Pharmacological Inhibition: Using KRIBB11, a selective inhibitor of HSF1, to block its activity.
  • Immunohistochemistry: To examine the protein expression levels of FAM3C, YY1, and HSF1 in human breast cancer tissues and adjacent normal tissues.

Datasets

The study utilized human breast cancer cell lines (MDA-MB-231 and BT-549) and human breast cancer tissues. No new benchmarks or datasets were introduced.

Key Insights and Ideas

  • A Novel FAM3C-YY1-HSF1 Axis: The study reveals a previously uncharacterized signaling cascade where FAM3C activates YY1, which in turn directly upregulates HSF1 transcription. This axis is central to promoting breast cancer cell proliferation and migration.
  • TGF-β as a Key Regulator: Transforming growth factor-beta (TGF-β) plays a critical role by upregulating FAM3C, HSF1, and YY1, thereby initiating the FAM3C-YY1-HSF1 pathway and driving cancer progression.
  • HSF1 as a Direct Target of YY1: The research provides strong evidence that YY1 directly binds to the HSF1 promoter, acting as a transcription factor to drive HSF1 expression.
  • Downstream Activation of Akt/Cyclin D1: The YY1-HSF1 axis ultimately leads to the activation of the Akt-Cyclin D1 pathway, which is a well-known driver of cell proliferation and survival.
  • Clinical Relevance: Elevated levels of FAM3C, YY1, and HSF1 were observed in human breast cancer tissues, underscoring the clinical significance of this pathway in the disease.

Key Results

  • FAM3C Promotes Proliferation and Migration: Overexpression of FAM3C in MDA-MB-231 cells significantly increased HSF1, pAkt, and Cyclin D1 protein levels, as well as HSF1 and Cyclin D1 mRNA levels. This correlated with increased cell proliferation and migration. Conversely, FAM3C silencing had the opposite effect.
  • TGF-β Induces the Pathway: TGF-β treatment upregulated FAM3C, HSF1, and YY1 expression in MDA-MB-231 cells, and FAM3C silencing attenuated TGF-β-induced HSF1 activation and proliferation.
  • YY1 Activates HSF1 Transcription: YY1 was shown to directly activate the HSF1 gene promoter, leading to increased HSF1 expression and subsequent promotion of proliferation and migration.
  • HSF1 Inhibition Blocks Progression: Inhibiting HSF1 with KRIBB11 abolished the stimulatory effects of FAM3C and TGF-β on cell proliferation and migration.
  • Clinical Validation: Immunohistochemical analysis of human breast cancer tissues revealed significantly higher levels of FAM3C, YY1, and HSF1 proteins compared to adjacent normal tissues.

Limitations and Future Work

  • Mechanism of FAM3C-YY1 Activation: While the study demonstrates that FAM3C upregulates YY1, the precise molecular mechanism by which FAM3C activates YY1 remains to be fully elucidated.
  • Circulating FAM3C: The authors note the difficulty in accurately detecting circulating FAM3C levels due to the lack of highly sensitive methods. Developing such methods would be crucial for its potential use as a diagnostic biomarker.
  • HSF1 Inhibitor Side Effects: The study acknowledges that HSF1 plays roles in regulating metabolism, and potential side effects like hyperglycemia should be considered when developing HSF1 inhibitors for cancer treatment.
  • Further Exploration of YY1's Role: While the study clarifies YY1's role in HSF1 activation, further research could delve deeper into other potential functions of YY1 in breast cancer pathogenesis.
  • Broader Tissue Relevance: While the study focused on breast cancer, exploring the FAM3C-YY1-HSF1 axis in other cancer types could reveal broader therapeutic potential.

Summary updated

Abstract

Family with sequence similarity three member C (FAM3C) (interleukin-like EMT inducer [ILEI]), heat shock factor 1 (HSF1) and Ying-Yang 1 (YY1) have been independently reported to be involved in the pathogenesis of various cancers. However, whether they are coordinated to trigger the development of cancer remains unknown. This study determined the role and mechanism of YY1 and HSF1 in FAM3C-induced proliferation and migration of breast cancer cells. In human MDA-MB-231 breast cancer cell line, transforming growth factor-β (TGFβ) up-regulated FAM3C, HSF1 and YY1 expressions. FAM3C overexpression promoted the proliferation and migration of MDA-MB-231 cells with YY1 and HSF1 up-regulation, whereas FAM3C silencing exerted the opposite effects. FAM3C inhibition repressed TGFβ-induced HSF1 activation, and proliferation and migration of breast cancer cells. YY1 was shown to directly activate HSF1 transcription to promote the proliferation and migration of breast cancer cells. YY1 silencing blunted FAM3C- and TGFβ-triggered activation of HSF1-Akt-Cyclin D1 pathway, and proliferation and migration of breast cancer cells. Inhibition of HSF1 blocked TGFβ-, FAM3C- and YY1-induced proliferation and migration of breast cancer cells. YY1 and HSF1 had little effect on FAM3C expression. Similarly, inhibition of HSF1 also blunted FAM3C- and TGFβ-promoted proliferation and migration of human breast cancer BT-549 cells. In human breast cancer tissues, FAM3C, YY1 and HSF1 protein expressions were increased. In conclusion, FAM3C activated YY1-HSF1 signalling axis to promote the proliferation and migration of breast cancer cells. Furthermore, novel FAM3C-YY1-HSF1 pathway plays an important role in TGFβ-triggered proliferation and migration of human breast cancer MDA-MB-231 cells.
BibTeX
@article{yang2019fam,
  author = {Weili Yang and Biaoqi Feng and Yuhong Meng and Junpei Wang and Bin Geng and Qinghua Cui and Hongquan Zhang and Yang Yang and Jichun Yang},
  title = {{FAM3C‐YY1 axis is essential for TGFβ‐promoted proliferation and migration of human breast cancer MDA‐MB‐231 cells via the activation of HSF1}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2019},
  doi = {10.1111/jcmm.14243},
}
Figure